Abstract:Neurodegenerative diseases are closely related to inflammatory and autoimmune events, suggesting that the dysregulation of the immune system is a key pathological factor. Both multiple sclerosis (MS) and Alzheimer's disease (AD) are characterized by infiltrating immune cells, activated microglia, astrocyte proliferation, and neuronal damage. Moreover, MS and AD share a common pro-inflammatory signature, characterized by peripheral leukocyte activation and transmigration to the central nervous system (CNS). MS and AD are both characterized by the accumulation of activated neutrophils in the blood, leading to progressive impairment of the blood–brain barrier. Having migrated to the CNS during the early phases of MS and AD, neutrophils promote local inflammation that contributes to pathogenesis and clinical progression. The role of circulating T cells in MS is well-established, whereas the contribution of adaptive immunity to AD pathogenesis and progression is a more recent discovery. Even so, blocking the transmigration of T cells to the CNS can benefit both MS and AD patients, suggesting that common adaptive immunity mechanisms play a detrimental role in each disease. There is also growing evidence that regulatory T cells are beneficial during the initial stages of MS and AD, supporting the link between the modulatory immune compartments and these neurodegenerative disorders. The number of resting regulatory T cells declines in both diseases, indicating a common pathogenic mechanism involving the dysregulation of these cells, although their precise role in the control of neuroinflammation remains unclear. The modulation of leukocyte functions can benefit MS patients, so more insight into the role of peripheral immune cells may reveal new targets for pharmacological intervention in other neuroinflammatory and neurodegenerative diseases, including AD.

miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.

Mirnas Participate in MS Pathological Processes and Its Therapeutic Response

MicroRNA in Multiple Sclerosis

MicroRNAs associated with the pathogenesis of multiple sclerosis

MicroRNAs As T Lymphocyte Regulators in Multiple Sclerosis

Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation

Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Exosomal Mirnas in Central Nervous System Diseases: Biomarkers, Pathological Mediators, Protective Factors and Therapeutic Agents.

MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis

The role of microRNAs involved in the disorder of blood–brain barrier in the pathogenesis of multiple sclerosis

MiRNA-based therapeutic potential in multiple sclerosis

Chemokines and Chemokine Receptors in Multiple Sclerosis

Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

T cells in the pathogenesis of multiple sclerosis and related therapy

Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease

Recent Advances of Long Noncoding RNAs Involved in the Development of Multiple Sclerosis.

Recent advances in understanding the pathogenesis and biological treatment of multiple sclerosis

MicroRNAs in autoimmune disease

Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis